Progenics Pharmaceuticals (PGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-1999 | 12-1998 | 12-1997 | 12-1996 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -496 | N/A | N/A | N/A |
| Depreciation Amortization | 918 | N/A | N/A | N/A |
| Accounts receivable | 488 | N/A | N/A | N/A |
| Other Working Capital | -441 | N/A | N/A | N/A |
| Other Operating Activity | 2,128 | 0 | 0 | 0 |
| Operating Cash Flow | $2,597 | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | -33,579 | N/A | N/A | N/A |
| PPE Investments | -1,043 | N/A | N/A | N/A |
| Investing Cash Flow | $-34,622 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Repayment | -108 | N/A | N/A | N/A |
| Common Stock Issued | 41,907 | N/A | N/A | N/A |
| Financing Cash Flow | $41,800 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 14,437 | N/A | N/A | N/A |
| End Cash Position | 24,213 | N/A | N/A | N/A |
| Net Cash Flow | $9,775 | $N/A | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | 2,597 | N/A | N/A | N/A |
| Capital Expenditure | -1,043 | N/A | N/A | N/A |
| Free Cash Flow | 1,555 | 0 | 0 | 0 |